Article

Cardiac Transplantation Followed by Dose-Intensive Melphalan and Autologous Stem-Cell Transplantation for Light Chain Amyloidosis and Heart Failure

Massachusetts General Hospital, Boston, MA, USA.
Transplantation (Impact Factor: 3.78). 10/2010; 90(8):905-11. DOI: 10.1097/TP.0b013e3181f10edb
Source: PubMed

ABSTRACT Patients with light chain (AL) amyloidosis who present with severe heart failure due to cardiac involvement rarely survive more than 6 months. Survival after cardiac transplantation is markedly reduced due to the progression of amyloidosis. Autologous stem-cell transplantation (ASCT) has become a common therapy for AL amyloidosis, but there is an exceedingly high treatment-related mortality in patients with heart failure.
We developed a treatment strategy of cardiac transplant followed by ASCT. Twenty-six patients were evaluated, and of 18 eligible patients, nine patients underwent cardiac transplantation. Eight of these patients subsequently received an ASCT.
Six of seven evaluable patients achieved a complete hematologic remission, and one achieved a partial remission. At a median follow-up of 56 months from cardiac transplant, five of seven patients are alive without recurrent amyloidosis. Their survival is comparable with 17,389 patients who received heart transplants for nonamyloid heart disease: 64% in nonamyloid vs. 60% in amyloid patients at 7 years (P=0.83). Seven of eight transplanted patients have had no evidence of amyloid in their cardiac allograft.
This demonstrates that cardiac transplantation followed by ASCT is feasible in selected patients with AL amyloidosis and heart failure, and that such a strategy may lead to improved overall survival.

0 Followers
 · 
109 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: Introduction: The treatment of immunoglobulin light-chain (AL) amyloidosis parallels that of multiple myeloma. Particular challenges not present in myeloma relate to amyloid-related organ damage, which greatly increases treatment-related toxicity and mortality. The management of patients with advanced organ involvement remains a huge challenge even in the era of novel agents with improved supportive care. Further, the limited number of direct comparisons of treatment in AL amyloidosis has meant that current clinical practice stems from retrospective studies and case reports. Areas covered: Here, current treatment options and future potential therapies in the management of AL amyloidosis are reviewed. A literature review has been performed on PubMed database and abstracts from recent scientific meetings with the search terms: ‘AL amyloidosis', ‘melphalan', ‘stem cell transplantation', ‘proteasome inhibitors' and ‘immunomodulatory drugs'. Expert opinion: Stem cell transplantation (SCT) should remain a preferred option for patients deemed eligible to undergo this technique safely. Unfortunately, only 20 – 25% of patients with AL amyloidosis are eligible for SCT with acceptably low mortality risk. Most patients, therefore, require cyclic multiple-agent chemotherapy, including immunomodulatory drugs, proteasome inhibitors and alkylators such as melphalan. Novel therapeutic approaches such as immunotherapy may soon be available with potential to reshape the treatment strategy of this serious disorder.
    02/2014; 2(3). DOI:10.1517/21678707.2014.881285
  • [Show abstract] [Hide abstract]
    ABSTRACT: Abstract Nearly half of AL amyloidosis patients have cardiac involvement, an independent predictor of poor prognosis. High-dose melphalan and autologous stem-cell transplantation (HDM/SCT) can induce complete hematologic responses and prolong survival in AL amyloidosis. Granulocyte colony-stimulating factor (G-CSF)-induced mobilization of peripheral blood stem cell (PBSC) in AL amyloidosis patients is associated with volume overload, arrhythmias and capillary leak syndrome. Plerixafor has a different mechanism of action and has non-overlapping toxicities with G-CSF. We describe our experience in five patients with AL amyloidosis and cardiac involvement who received plerixafor with G-CSF for PBSC mobilization. Median age was 56 years; two patients had undergone heart transplantation within the year prior to HDM/SCT. Three patients received plerixafor after an initial trial of mobilization with G-CSF alone. No patient had any significant toxicities during mobilization and PBSC collection. The median total yield of PBSCs collected was 5.9 × 10(6) CD34+ cells/kg; the median number of leukapheresis days was 2. Neutrophil engraftment after HDM/SCT occurred at a median of nine days, platelet engraftment at a median of 13 days. Plerixafor was effective and well tolerated when used upfront or as rescue for PBSC mobilization in AL amyloidosis patients with cardiac involvement.
    Amyloid: the international journal of experimental and clinical investigation: the official journal of the International Society of Amyloidosis 04/2014; 21(3). DOI:10.3109/13506129.2014.900486 · 2.51 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: We conducted a review of patients undergoing heart transplantation (HT) at our institution for amyloid cardiomyopathy (ACM) between 2008 and 2013. Complete follow-up was available for all patients. Nineteen patients with ACM underwent HT during the study period, accounting for 9.4% of all HT performed at our institution during this period. Amyloid subtype was light chain (AL) in 9 patients and transthyretin (ATTR) in 10 (2 wild-type, 7 familial, 1 unknown). Eight of nine patients with AL amyloidosis began chemotherapy prior to HT, six have resumed chemotherapy since HT, and five have undergone autologous stem cell transplantation. Most recent free light chain levels in AL patients decreased by a median of 85% from peak values. Only one patient developed recurrent graft amyloidosis, occurring at 3.5 years post-HT and asymptomatic. After a median follow-up of 380 days, 17 (89.5%) patients are alive. To our knowledge, this is the largest single-center series reported of ACM patients undergoing HT in the modern era. Our results suggest that acceptable outcomes following HT can be achieved in the short-to-intermediate term and that this is a feasible option for end-stage ACM with careful patient selection and aggressive control of amyloidogenic light chains in AL patients.
    American Journal of Transplantation 02/2015; 15(3). DOI:10.1111/ajt.13025 · 6.19 Impact Factor

Full-text (2 Sources)

Download
20 Downloads
Available from
Jun 2, 2014

Similar Publications